Close Menu

marketing agreement

The deal will take Novartis into the blood genotyping market.

LabCorp will be XDx's preferred third-party, non-hospital provider for phlebotomy and specimen processing for all XDx AlloMap molecular expression tests conducted in North America.

The agreement follows yesterday's announcement of a similar pact with Ion Torrent.

As part of the deal, FIND will have rights to sell the HIV test, as well as Cepheid's Xpert chlamydia and gonorrhea tests, which will be sold at a discount to the public and the not-for-profit sector in some countries.

Ion Torrent will offer software from Partek and DNAStar directly through its online store, and it has inked a service and support deal with BioTeam for the Ion Torrent Server and Torrent Suite Software.

Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US.

The instruments were acquired just three months ago by Cellectis from Cyto Pulse Sciences.

LightArray will offer a variety of Aushon's multiplex biomarker products and services in China.

Rosetta has regained US commercial rights from Prometheus for its miRview mets, miRview squamous, and miRview meso tests.

Cepheid will receive $5 million in an upfront payment and $3 million in milestone payments over the next 12 months as part of the deal, while Novartis would have exclusive global distribution rights to the test upon its commercialization in the US.


A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.